American Journal of Kidney Diseases
Volume 50, Issue 5 , Pages 691-695 , November 2007

Imperial or Empirical Measures of Dialysis Quality?

  • Klemens B. Meyer, MD
    • ,
  • Dana C. Miskulin, MD, MS

      Affiliations

    • Corresponding Author InformationAddress correspondence to Dana C. Miskulin, MD, Division of Nephrology, Tufts-New England Medical Center, Box #391, Boston, MA 02111.

References 

  1. Andersen HC: Andersen’s Fairy Tales. Available at: www.gutenberg.org. Accessed September 18, 2007.
  2. Frederick PR, Maxey NL, Clauser SB, Sugarman JR. Developing dialysis facility-specific performance measures for public reporting. Health Care Financ Rev. 2002;23:37–50
  3. McClellan WM, Frederick PR, Helgerson SD, Hayes RP, Ballard DJ, McMullan M. A data-driven approach to improving the care of in-center hemodialysis patients. Health Care Financing Rev. 1995;16:129–140
  4. Fink JC, Blahut SA, Briglia AE, Gardner JF, Light PD. Effect of center-versus patient-specific factors on variations in dialysis adequacy. J Am Soc Nephrol. 2001;12:164–169
  5. Fink JC, Hsu VD, Zhan M, et al. Center effects in anemia management of dialysis patients. J Am Soc Nephrol. 2007;18:646–653
  6. Spolter YS, Seliger SL, Zhan M, Hsu VD, Walker LD, Fink JC. The relationship between dialysis performance measures: adequacy and anemia management. Am J Kidney Dis. 2007;50:774–781
  7. National Institutes of Health: Morbidity and mortality of dialysis. NIH Consensus Statement Online, November 1-3, 1993, 11:1-33
  8. Renal Physicians Association: Clinical practice guideline on adequacy of hemodialysis. Clinical Policy, 1993
  9. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. Am J Kidney Dis. 2001;37(suppl 1):S182–S238
  10. Centers for Medicare & Medicaid Services. 2006 Annual Report: ESRD Clinical Performance Measures Project. Baltimore, MD: Centers for Medicare & Medicaid Services, Office of Clinical Standards & Quality; 2006;
  11. McClellan WM, Soucie J, Flanders W. Mortality in end-stage renal disease is associated with facility-to-facility differences in adequacy of hemodialysis. J Am Soc Nephrol. 1998;9:1940–1947
  12. Rocco MV, Frankenfield DL, Hopson SD, McClellan WM. Relationship between clinical performance measures and outcomes among patients receiving long-term hemodialysis. Ann Intern Med. 2006;145:512–519
  13. Tentori F, Hunt WC, Rohrscheib M, et al. Which targets in clinical practice guidelines are associated with improved survival in a large dialysis organization?. J Am Soc Nephrol. 2007;18:2377–2384
  14. Wolfe RA, Hulbert-Shearon TE, Ashby VB, Mahadevan S, Port FK. Improvements in dialysis patient mortality are associated with improvements in urea reduction ratio and hematocrit, 1999 to 2002. Am J Kidney Dis. 2005;45:127–135
  15. Meyer KB, Kassirer JP. Squeezing more cost and care out of dialysis: our patients would pay the price. Am J Med. 2002;112:232–234
  16. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584–590
  17. Beusterien KM, Nissenson AR, Port FK, Kelly M, Steinwald B, Ware JE. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol. 1996;7:763–773
  18. Furuland H, Linde T, Ahlmen J, Christensson A, Strombom U, Danielson BG. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant. 2003;18:353–361
  19. Jones M, Ibels L, Schenkel B, Zagari M. Impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis. Kidney Int. 2004;65:757–767
  20. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis. 2006;47(suppl 3):S11–S145
  21. Brewster UC. Intravenous iron therapy in end-stage renal disease. Semin Dial. 2006;19:285–290
  22. Krishnan M, Adams E. Operationalizing anemia management: organizing the program and coordinating the team. Nephrol Nurs J. 2003;30:567–570
  23. Walter LC, Davidowitz NP, Heineken PA, Covinsky KE. Pitfalls of converting practice guidelines into quality measures: lessons learned from a VA performance measure. JAMA. 2004;291:2466–2470
  24. Bass EB, Wills S, Fink NE, et al. How strong are patients’ preferences in choices between dialysis modalities and doses?. Am J Kidney Dis. 2004;44:695–705
  25. Sankarasubbaiyan S, Holley JL. An analysis of the increased demands placed on dialysis health care team members by functionally dependent hemodialysis patients. Am J Kidney Dis. 2000;35:1061–1067
  26. Garg PP, Frick KD, Diener-West M, Powe NR. Effect of the ownership of dialysis facilities on patients’ survival and referral for transplantation. N Engl J Med. 1999;341:1653–1660
  27. Szczech LA, Klassen PS, Chua B, et al. Associations between CMS’s Clinical Performance Measures project benchmarks, profit structure, and mortality in dialysis units. Kidney Int. 2006;69:2094–2100
  28. Casalino LP. The unintended consequences of measuring quality on the quality of medical care. N Engl J Med. 1999;341:1147–1150
  29. Hayward RA. Performance measurement in search of a path. N Engl J Med. 2007;356:951–953
  30. Miskulin DC, Meyer KB, Athienites NV, et al. Comorbidity and other factors associated with modality selection in incident dialysis patients: the CHOICE Study (Choices for Healthy Outcomes in Caring for End-Stage Renal Disease). Am J Kidney Dis. 2002;39:324–336

PII: S0272-6386(07)01250-4

doi: 10.1053/j.ajkd.2007.09.008

American Journal of Kidney Diseases
Volume 50, Issue 5 , Pages 691-695 , November 2007

Article Tools